Thompson Davis & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Thompson Davis & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-134	Closed	-$20K	–	1086
2017 Q3	$20K	Buy	134 +24	+22%	+$3.61K	0.04%	487
2017 Q2	$14K	Hold	110	–	–	0.02%	579
2017 Q1	$12K	Hold	110	–	–	0.02%	651
2016 Q4	$8K	Buy	110 +49	+80%	+$3.99K	0.01%	758
2016 Q3	$5K	Hold	61	–	–	0.01%	846
2016 Q2	$5K	Hold	61	–	–	0.01%	794
2016 Q1	$5K	Hold	61	–	–	0.01%	800
2015 Q4	$8K	Hold	61	–	–	0.01%	727
2015 Q3	$6K	Hold	61	–	–	0.01%	807
2015 Q2	$8K	Hold	61	–	–	0.01%	784
2015 Q1	$7K	Hold	61	–	–	0.01%	833
2014 Q4	$7K	Buy	+61	New	+$6.87K	0.01%	859

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Thompson Davis & Co's VRTX Position: Q4 2017 in Review

Thompson Davis & Co sold out of Vertex Pharmaceuticals (VRTX) in Q4 2017, closing a stake of 134 shares — an estimated $20K sold.

Thompson Davis & Co first reported a position in VRTX in Q4 2014 and held it in 12 quarters. The position peaked at $20K in Q3 2017. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

Thompson Davis & Co reported no remaining Vertex Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Thompson Davis & Co sold 134 Vertex Pharmaceuticals shares in Q4 2017, an estimated $20K.
Thompson Davis & Co first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 12 quarters.
Thompson Davis & Co's Vertex Pharmaceuticals position peaked at $20K in Q3 2017.
644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.